News
KZIA
--
0.00%
--
Edison issues ADR outlook on Kazia Therapeutics (KZIA)
LONDON, UK / ACCESSWIRE / September 2, 2020 / We are reinitiating on Kazia Therapeutics (NASDAQ:KZIA), which is entering late-stage trials for its lead product, paxalisib, for glioblastoma multiforme (GBM).
ACCESSWIRE · 09/02 14:15
We're Hopeful That Kazia Therapeutics (ASX:KZA) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Kazia Therapeutics...
Simply Wall St. · 09/01 06:23
5 Stocks To Watch For August 24, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 08/24 10:12
A Peek Into The Markets: US Stock Futures Surge As FDA Authorizes Convalescent Plasma For Coronavirus Treatment
Pre-open movers
Benzinga · 08/24 10:12
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant
PR Newswire · 08/24 01:30
FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant glioma, which inclu
Benzinga · 08/24 01:14
OpGen leads healthcare gainers; iBio and Can-Fite BioPharma among losers
Gainers: OpGen (OPGN) +28%. Kazia Therapeutics (KZIA) +14%. CureVac (CVAC) +14%. Ontrak (OTRK) +13%. Zosano Pharma (ZSAN) +12%.Losers: Teligent (TLGT) -18%. iBio (IBIO) -13%. Artelo Biosciences (ARTL) -11%. Can-Fite BioPharma (CANF) -9%. Allied Healthcare Products (AHPI)
Seekingalpha · 08/20 15:02
LB, MAG among premarket gainers
Kazia Therapeutics (KZIA) +31% on U.S. accelerated review tag for lead drug.OpGen (OPGN) +42% on launch of COVID-19 test in Europe.Allied Esports Entertainment (AESE) +14% on Esports betting licensing agreement with GRID.Streamline Health
Seekingalpha · 08/20 12:21
Kazia Therapeutics up 21% on U.S. accelerated review tag for lead drug
Nano cap Kazia Therapeutics Limited (KZIA) jumps 21% premarket on robust volume in reaction to Fast Track status in the U.S. for lead drug paxalisib for a type of brain cancer called
Seekingalpha · 08/20 11:36
US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma
PR Newswire · 08/20 01:30
Kazia up big on Rare Pediatric Disease tag in U.S. for paxalisib
Thinly traded nano cap Kazia Therapeutics (NASDAQ:KZIA) jumps 138% premarket on increased volume in reaction to its disclosure that the FDA has granted Rar
seekingalpha · 08/07 15:58
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalis
PR Newswire · 08/07 14:30
Denovo Biopharma's enzastaurin Fast Track'd for brain tumor
The FDA designates privately held Denovo Biopharma's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblas
seekingalpha · 07/17 17:18
Kazia Shares Halted On Volatility, Up 33%
Benzinga · 07/15 18:20
Kazia Shares Resume Trading; Move Up, Shares Up 33%
Benzinga · 07/15 18:19
Kazia Therapeutics Shares Halted On Volatility At 2:14 p.m. EDT, Up 21%, After Traders Circulate Promotional Twitter Commentary
Benzinga · 07/15 18:18
Kazia Presents Further Paxalisib, Cantrixil Data At AACR, Reinforcing Positive Efficacy Signals For Both Drugs
SYDNEY, June 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing
Benzinga · 06/22 14:31
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
PR Newswire · 06/22 05:39
Kazia Therapeutics Shares Volatile Following Press Release Highlighting Paxalisib Phase 2 Data At ASCO
Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly
Benzinga · 06/01 14:39
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
PR Newswire · 06/01 01:45